Autologous Stem Cell Transplantation in Hodgkin Lymphoma—Latest Advances in the Era of Novel Therapies

SIMPLE SUMMARY: Standard second-line therapy for fit patients with relapsed and/or refractory Hodgkin lymphoma has long consisted of salvage therapy followed by autologous stem cell transplantation in responding patients. The introduction of the novel agents brentuximab vedotin, nivolumab, and pembr...

Descripción completa

Detalles Bibliográficos
Autores principales: Samara, Yazeed, Mei, Matthew
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8996995/
https://www.ncbi.nlm.nih.gov/pubmed/35406509
http://dx.doi.org/10.3390/cancers14071738

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8996995/
https://www.ncbi.nlm.nih.gov/pubmed/35406509
http://dx.doi.org/10.3390/cancers14071738

Ejemplares similares